Nektar Therapeutics announced today new results from its Phase 2b REZOLVE-AA study testing rezpegaldesleukin (REZPEG)—an experimental immune-modulating drug—in adults with…
Eli Lilly (Lilly) recently shared 52-week results from its Phase 3 clinical trial examining oral baricitinib (Olumiant®) 4 mg for…
The National Alopecia Areata Foundation (NAAF) is thrilled to report that two recent Student Internship Awardees have had their NAAF-supported…
Sun Pharmaceutical Industries Limited (Sun Pharma) today announced LEQSELVI™ (deuruxolitinib) is now commercially available for the treatment of severe alopecia…
UC Santa Cruz alumni at the forefront of alopecia research and advocacy NAAF President & CEO Nicole Friedland and NAAF…
Q32 Bio announced that it has received a Fast Track designation for bempikibart, its investigational treatment for alopecia areata (AA),…
NAAF is thrilled to announce the recipients of the 2024 Early Career Awards and Research Grants! Three investigators have been…
Alopecia areata (AA) took center stage at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. NAAF…
Last year, Nicole Friedland, NAAF President and CEO, participated in an expert steering committee, the Alopecia Areata Consensus Task Force,…
Today, the U.S. Food and Drug Administration (FDA) approved LEQSELVI™ (deuruxolitinib) for alopecia areata, marking the third FDA-approved treatment for…
